Located in the Presbyterian Health Foundationâs Research Park, Charlesson is an Oklahoma-based pharmaceutical company actively engaged in the development of therapeutics for treating debilitating ophthalmic diseases. The fim's product pipeline includes pharmaceutical treatments for Age-Related Macular Degeneration, Diabetic Retinopathy, Ocular Inflammation, Angiogenesis, and systemic diabetes. Charlessonâs lead candidate, CLT-005, is for the treatment of Dry AMD, for which there is no therapeutic currently approved. In addition to drug development, Charlesson also offers preclinical contract research with unique capabilities for ophthalmic testing such as: Angiogenesis Models Diabetic Models Macular Degeneration Models Retinal Degeneration Models in-vitro Studies Various Assa
